Old Web
English
Sign In
Acemap
>
authorDetail
>
Yasser Mostafa Kamel
Yasser Mostafa Kamel
Novartis
Eltrombopag
Medicine
Carboplatin
Chemotherapy
Placebo
3
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
2017
International Journal of Hematology
Eric S. Winer
Howard Safran
Boguslawa Karaszewska
Sebastian Bauer
Dilawar Khan
Steffen Doerfel
Paul Burgess
Stacey Kalambakas
Yasser Mostafa Kamel
Frederic Forget
Show All
Source
Cite
Save
Citations (14)
Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability
2015
Blood
Moshe Mittelman
Uwe Platzbecker
Boris Afanasyev
Sebastian Grosicki
Raymond Sm Wong
Achilles Anagnostopoulos
Benjamin Brenner
Claudio Denzlinger
Giuseppe Rossi
Arnon Nagler
Ana Rosell Mas
Frank Mannino
Nicole L. Stone
Geoffrey Chan
Yasser Mostafa Kamel
Dominik Selleslag
Show All
Source
Cite
Save
Citations (1)
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study.
2012
Journal of Clinical Oncology
Eric S. Winer
Howard Safran
Boguslawa Karaszewska
Donald A. Richards
Lee Hartner
Frederic Forget
Rodryg Ramlau
Kirushna Kumar
Bhabita Mayer
Brendan M. Johnson
C. Messam
Yasser Mostafa Kamel
Show All
Source
Cite
Save
Citations (5)
1